Many antiarrhythmic drugs have been said to increase the ventricular defibrillation threshold (DFT) . Although lidocaine and /or mexiletine are usually administered to treat arrhythmic patients who are taking another antiar-rythmic agent, there have been no previous studies concerning the combined effects of these drugs. The effect of lidocaine and mexiletine combined with flecainide on DFT was investigated in the present study. Experiments were performed on 16 mongrel dogs under general anesthesia with pentobarbital. Flecainide 2 mg/kg was administered intravenously as the loading dose, then 2 mg/kg/hr was given subsequently. Next, lidocaine (n = 8) or mexiletine (n = 8), 1, 2, 3, 4, 5 mg/kg was administered every 10 min. In these two groups, fibrillation/defibrillation trials were repeated. The heart was allowed to fibrillate for a total of 20 sec by applying the fibrilation inducing electrodes to the heart. Energy levels of 2, 3, 5, 7, 10, 20, and 30 joule maximum were used for the defibrillation. The minimum energy inducing the ventricular fibrilation was defined as FIE and that of defibrillation as DFT. Although the FIE increased correlating to the increase of the concentrations of three drugs, no statistical correlations were found between the lidocaine and mexiletine concentrations and the DFT.
In conclusion, although the present study was performed in a canine model, results might be applied in clinical practice. In patients, who had been treated with flecainide, showing malignant ventricular arrhythmia during anesthesia or in ICU, lidocaine or mexiletine can be administered without risk of increasing the DFT.
View full abstract